vs
豪洛捷（HOLX）与Masco（MAS）财务数据对比。点击上方公司名可切换其他公司
Masco的季度营收约是豪洛捷的1.8倍（$1.9B vs $1.0B），豪洛捷净利率更高（17.1% vs 11.9%，领先5.2%），Masco同比增速更快（6.5% vs 2.5%），过去两年豪洛捷的营收复合增速更高（1.5% vs -4.2%）
豪洛捷是一家总部位于美国的医疗科技企业，核心业务聚焦女性健康领域，旗下产品涵盖诊断、外科手术及医学影像类专业医疗设备，为全球各地的医疗场景提供优质技术与产品支持。
美国家居建材企业Masco主营家装及新建住宅市场相关产品，旗下拥有20余家子公司，在全球运营近80座生产工厂，其中美国本土近60座，海外地区超20座。公司1969年于纽交所挂牌上市，后实现快速增长，成功跻身美国财富500强榜单。
HOLX vs MAS — 直观对比
营收规模更大
MAS
是对方的1.8倍
$1.0B
营收增速更快
MAS
高出4.0%
2.5%
净利率更高
HOLX
高出5.2%
11.9%
两年增速更快
HOLX
近两年复合增速
-4.2%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $1.9B |
| 净利润 | $179.1M | $228.0M |
| 毛利率 | 56.0% | 35.8% |
| 营业利润率 | 22.6% | 16.5% |
| 净利率 | 17.1% | 11.9% |
| 营收同比 | 2.5% | 6.5% |
| 净利润同比 | -10.9% | 14.5% |
| 每股收益（稀释后） | $0.79 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HOLXMAS
| Q1 26 | — | $1.9B | ||
| Q4 25 | $1.0B | $1.8B | ||
| Q3 25 | $1.0B | $1.9B | ||
| Q2 25 | $1.0B | $2.1B | ||
| Q1 25 | $1.0B | $1.8B | ||
| Q4 24 | $1.0B | $1.8B | ||
| Q3 24 | $988.0M | $2.0B | ||
| Q2 24 | $1.0B | $2.1B |
净利润HOLXMAS
| Q1 26 | — | $228.0M | ||
| Q4 25 | $179.1M | $165.0M | ||
| Q3 25 | $187.2M | $189.0M | ||
| Q2 25 | $194.9M | $270.0M | ||
| Q1 25 | $-17.4M | $186.0M | ||
| Q4 24 | $201.0M | $182.0M | ||
| Q3 24 | $178.6M | $167.0M | ||
| Q2 24 | $194.5M | $258.0M |
毛利率HOLXMAS
| Q1 26 | — | 35.8% | ||
| Q4 25 | 56.0% | 33.9% | ||
| Q3 25 | 55.6% | 34.2% | ||
| Q2 25 | 56.3% | 37.6% | ||
| Q1 25 | 37.5% | 35.8% | ||
| Q4 24 | 56.8% | 34.8% | ||
| Q3 24 | 56.4% | 36.6% | ||
| Q2 24 | 55.4% | 37.5% |
营业利润率HOLXMAS
| Q1 26 | — | 16.5% | ||
| Q4 25 | 22.6% | 13.8% | ||
| Q3 25 | 22.6% | 15.8% | ||
| Q2 25 | 24.9% | 20.1% | ||
| Q1 25 | -0.7% | 15.9% | ||
| Q4 24 | 22.5% | 15.9% | ||
| Q3 24 | 23.3% | 18.0% | ||
| Q2 24 | 24.1% | 19.0% |
净利率HOLXMAS
| Q1 26 | — | 11.9% | ||
| Q4 25 | 17.1% | 9.2% | ||
| Q3 25 | 17.8% | 9.9% | ||
| Q2 25 | 19.0% | 13.2% | ||
| Q1 25 | -1.7% | 10.3% | ||
| Q4 24 | 19.7% | 10.0% | ||
| Q3 24 | 18.1% | 8.4% | ||
| Q2 24 | 19.2% | 12.3% |
每股收益（稀释后）HOLXMAS
| Q1 26 | — | — | ||
| Q4 25 | $0.79 | $0.81 | ||
| Q3 25 | $0.84 | $0.90 | ||
| Q2 25 | $0.86 | $1.28 | ||
| Q1 25 | $-0.08 | $0.87 | ||
| Q4 24 | $0.87 | $0.85 | ||
| Q3 24 | $0.75 | $0.77 | ||
| Q2 24 | $0.82 | $1.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.4B | — |
| 总债务越低越好 | $2.5B | $2.9B |
| 股东权益账面价值 | $5.2B | $27.0M |
| 总资产 | $9.2B | $5.2B |
| 负债/权益比越低杠杆越低 | 0.48× | 109.07× |
8季度趋势，按日历期对齐
现金及短期投资HOLXMAS
| Q1 26 | — | — | ||
| Q4 25 | $2.4B | $647.0M | ||
| Q3 25 | $2.2B | $559.0M | ||
| Q2 25 | $1.9B | $390.0M | ||
| Q1 25 | $1.6B | $377.0M | ||
| Q4 24 | $2.0B | $634.0M | ||
| Q3 24 | $2.3B | $646.0M | ||
| Q2 24 | $2.4B | $398.0M |
总债务HOLXMAS
| Q1 26 | — | $2.9B | ||
| Q4 25 | $2.5B | $2.9B | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.5B | $2.9B | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | — |
股东权益HOLXMAS
| Q1 26 | — | $27.0M | ||
| Q4 25 | $5.2B | $-185.0M | ||
| Q3 25 | $5.0B | $-78.0M | ||
| Q2 25 | $4.8B | $-84.0M | ||
| Q1 25 | $4.6B | $-254.0M | ||
| Q4 24 | $4.8B | $-279.0M | ||
| Q3 24 | $5.1B | $-88.0M | ||
| Q2 24 | $5.0B | $-26.0M |
总资产HOLXMAS
| Q1 26 | — | $5.2B | ||
| Q4 25 | $9.2B | $5.2B | ||
| Q3 25 | $9.0B | $5.3B | ||
| Q2 25 | $8.8B | $5.3B | ||
| Q1 25 | $8.5B | $5.1B | ||
| Q4 24 | $8.7B | $5.0B | ||
| Q3 24 | $9.2B | $5.3B | ||
| Q2 24 | $8.9B | $5.4B |
负债/权益比HOLXMAS
| Q1 26 | — | 109.07× | ||
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.49× | — | ||
| Q2 24 | 0.51× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $229.9M | — |
| 自由现金流经营现金流 - 资本支出 | $215.2M | — |
| 自由现金流率自由现金流/营收 | 20.5% | — |
| 资本支出强度资本支出/营收 | 1.4% | 1.8% |
| 现金转化率经营现金流/净利润 | 1.28× | — |
| 过去12个月自由现金流最近4个季度 | $1.0B | — |
8季度趋势，按日历期对齐
经营现金流HOLXMAS
| Q1 26 | — | — | ||
| Q4 25 | $229.9M | $418.0M | ||
| Q3 25 | $355.1M | $456.0M | ||
| Q2 25 | $343.3M | $306.0M | ||
| Q1 25 | $169.4M | $-158.0M | ||
| Q4 24 | $189.3M | $407.0M | ||
| Q3 24 | $367.0M | $416.0M | ||
| Q2 24 | $405.8M | $346.0M |
自由现金流HOLXMAS
| Q1 26 | — | — | ||
| Q4 25 | $215.2M | $371.0M | ||
| Q3 25 | $341.4M | $415.0M | ||
| Q2 25 | $330.5M | $270.0M | ||
| Q1 25 | $153.9M | $-190.0M | ||
| Q4 24 | $172.5M | $351.0M | ||
| Q3 24 | $350.6M | $378.0M | ||
| Q2 24 | $385.3M | $303.0M |
自由现金流率HOLXMAS
| Q1 26 | — | — | ||
| Q4 25 | 20.5% | 20.7% | ||
| Q3 25 | 32.5% | 21.6% | ||
| Q2 25 | 32.3% | 13.2% | ||
| Q1 25 | 15.3% | -10.5% | ||
| Q4 24 | 16.9% | 19.2% | ||
| Q3 24 | 35.5% | 19.1% | ||
| Q2 24 | 38.1% | 14.5% |
资本支出强度HOLXMAS
| Q1 26 | — | 1.8% | ||
| Q4 25 | 1.4% | 2.6% | ||
| Q3 25 | 1.3% | 2.1% | ||
| Q2 25 | 1.3% | 1.8% | ||
| Q1 25 | 1.5% | 1.8% | ||
| Q4 24 | 1.6% | 3.1% | ||
| Q3 24 | 1.7% | 1.9% | ||
| Q2 24 | 2.0% | 2.1% |
现金转化率HOLXMAS
| Q1 26 | — | — | ||
| Q4 25 | 1.28× | 2.53× | ||
| Q3 25 | 1.90× | 2.41× | ||
| Q2 25 | 1.76× | 1.13× | ||
| Q1 25 | — | -0.85× | ||
| Q4 24 | 0.94× | 2.24× | ||
| Q3 24 | 2.05× | 2.49× | ||
| Q2 24 | 2.09× | 1.34× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
MAS
暂无分部数据
